Pulmonary Arterial Hypertension (PAH)

Madhavan.S[1], Pazhanivel.G[2], R. Kalaivani[3], Nepolean.R[4]
[1,2,3,4]*Thanthai Roever college of Pharmacy*

Abstract— **Pulmonary arterial hypertension (PAH) is a chronic, progressive, and life-threatening disorder characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, ultimately leading to right ventricular failure and death if untreated. Over the past two decades, substantial advances have been made in understanding the molecular and cellular mechanisms underlying PAH, resulting in improved diagnostic strategies and targeted therapies. Despite these advancements, PAH remains incurable and is associated with significant morbidity and mortality. This assignment provides a comprehensive overview of PAH, including its epidemiology, pathophysiology, classification, clinical presentation, diagnostic evaluation, treatment modalities, and emerging research trends.**

I. INTRODUCTION

Pulmonary arterial hypertension is a particular subtype of pulmonary hypertension characterized hemodynamically by a mean pulmonary arterial pressure (mPAP) exceeding 20 mmHg at rest, pulmonary vascular resistance (PVR) [?]3 Wood units and pulmonary artery wedge pressure [?]15 mmHg when measured by right heart catheterization. The small pulmonary arteries are the main sites of PAH, where vascular remodeling leads to a narrowing and eventual obstruction of the arteries. Despite the fact that PAH is a rare disease, its effect on patient quality of life and survival is significant. The condition can be idiopathic or hereditary or secondary to other diseases. It is important to recognize this early because most of the time, by the time it is diagnosed, the disease is at an advanced stage.

II. EPIDEMIOLOGY

The prevalence of PAH is estimated to be 15-50 cases per million adults worldwide. It is generally more common in women than men with a female to male ratio of about 2:1. The mean age of diagnosis has since risen and is currently at the fifth and sixth decades of life. Examples of risk factors are genetic predisposition, connective tissue diseases, congenital heart disease, portal hypertension, HIV infection, and exposure to some drugs and toxins. PAH is a chronic condition with a large healthcare burden even though it is rare. Physiology and Anatomy of the Pulmonary Circulation. The blood in the lungs moves in a way that helps in the effective exchange of gases. It is of low pressure, low resistance affinity to systemic circulation. The right ventricle blood in the pulmonary arteries drains to a dense capillary bed around the alveoli. Endothelial cells are important in ensuring vascular homeostasis by secreting vasodilators like nitric oxide and prostacyclin, and vasoconstrictors like endothelin-1. The imbalance of these mediators may lead to disruption of the vascular tone and cause disease.

Pathophysiology of PAH The development of PAH is multifactorial and includes a combination of several processes that affect each other: Endothelial Dysfunction The endothelial cells lose capacity to maintain vascular tone properly, leading to the excessive production of vasodilators and the excessive release of vasoconstrictors. Vascular Remodelling The alterations in the structure of the pulmonary arteries involve the proliferation of smooth muscle, fibrosis, and constriction of the lumen of the vessels. Such alterations make it harder to carry blood. Thrombosis and Inflammation. Vascular injury and remodeling involve the effect of inflammatory mediators. Obstruction of pulmonary vessels is further increased by in situ thrombosis. Genetic Factors The most frequent genetic defect in hereditary PAH is mutations in the BMPR2 gene. There are other possible genes that include: ALK1 and ENG. Hemodynamic Consequences High right ventricular afterload is caused by increased pulmonary vascular resistance. With time, hypertrophy and subsequent failure of the right ventricle occurs.

III. CLASSIFICATION OF PULMONARY HYPERTENSION

Pulmonary Hypertension is classified as follows. According to the World Health Organization, there are five categories of pulmonary hypertension: 1. Group 1: Pulmonary arteries hypertension. 2. Group 2: Pulmonary hypertension as a result of left heart disease. 3. Group 3: Hypoxia and lung diseases: pulmonary hypertension. 4. Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) 5. Group 5: Unclear/ multifactorial mechanisms of pulmonary hypertension. This categorization assists in the diagnosis and treatment plan.

Etiology And Risk Factors

PAH may develop due to a variety of reasons:

- Idiopathic PAH: No known cause.
- Heritable PAH: Relates to genetic mutations.
- Related PAH: Related to: o Diseases of connective tissue (e.g., systemic sclerosis) o congenital heart diseases o Portal hypertension o HIV infection • PAH caused by drugs: Caused by appetite suppressants and some toxins.

Clinical Manifestations

The PAH is usually not specific in its symptoms, resulting in a late diagnosis. Early Symptoms * Exertional dyspnea * Fatigue * Weakness Advanced Symptoms * Chest pain * Syncope * Palpitations * Peripheral edema Physical Findings * Loud second heart sound (P2) * Right ventricular heave * Jugular venous distension * In severe cases, hepatomegaly and ascites. Diagnostic Evaluation The diagnosis needs to be systematic: Non-invasive Tests * Echocardiography: The screening tool of the first line. * Electrocardiogram (ECG): Could have right heart strain. * X-ray of the chest: Pulmonary arteries are enlarged. Invasive Testing * Right Heart Catheterization: The best way to prove diagnosis. Additional Tests * Pulmonary function tests * CT scan of the chest the V/Q scan Ventilation-perfusion (V/Q) scan. * Biomarkers (BNP or NT-proBNP).

Disease Severity and Prognostic Indicators

The severity is determined based on WHO functional classification system: * class X - no physical activity restriction. * Class II: Mild limitation * Class III: Marked limitation * Class IV: Symptoms at rest Right ventricular functioning, exercise capacity, and hemodynamic measurements are some of the prognostic factors.

Management And Treatment

The management process is based on the idea of enhancing symptoms, reducing the rate of disease progression, and augmenting survival. General Measures * Lifestyle modification * Supervised aerobic exercise training. * Oxygen therapy * Fluid management diuretics. Pharmacological Therapy Endothelin Receptor Antagonists. Less vasoconstriction (e.g., bosentan, ambrisentan) Phosphodiesterase-5 Inhibitors Improve nitric oxide transmission (e.g., sildenafil, tadalafil) Prostacyclin Analogues Encourage vascular permeability (e.g. epoprostenol, treprostinil) Soluble Guanylate Cyclase Stimulators. Enhance vascular relaxation (e.g., riociguat)

Combination Therapy

Combination therapy with various classes of drugs has demonstrated better results in a large number of patients. Surgical and Advanced. * Lung transplantation * In some cases, atrial septostomy. Complications RAW/progressive PAH may result in serious complications: * Right heart failure * Arrhythmias * Hemoptysis * Thromboembolism * Sudden cardiac death

Recent Advances and Research

Recent studies focus on: * Novel molecular pathways * Anti-inflammatory medications. BMPR2 mutations gene therapy. * Stem cell therapy * Individualized medicine methods. New combinations of drugs and treatment strategies are still being investigated in clinical trials.

IV. PROGNOSIS AND SURVIVAL

PAH had a dismal prognosis in the past with a median survival of under 3 years. Modern therapies have led to better survival. Early treatment and diagnosis are some of the factors that can affect outcomes.

Prevention and Screening PAH may be prevented;however, it can be detected at an early age in high-risk categories:

- Diseases that relate to connective tissue in the patients. Individuals that have family history of PAH.
- Congenital heart disease patients. In these groups, it is advisable that screening should be done regularly using echocardiography.

V. LIFESTYLE MODIFICATION

There is some limited but encouraging evidence that aerobic exercise and modified yoga may be useful lifestyle interventions for people with pulmonary arterial hypertension (PAH), although the overall evidence is yet to be fully developed. The most significant evidence is from a randomized controlled trial (9) involving 24 women with a mean age of 54.4 years who had PAH. After a 10-week supervised aerobic exercise program (30-45 minutes of treadmill walking for three days per week at 70-80% heart rate reserve), the patients reported a significant improvement in the severity of fatigue ($p = 0.03$) and increased physical activity ($p < 0.05$) when compared to a control group who received educational sessions. Additional evidence comes from (10) who demonstrated the safety and feasibility of a modified yoga practice in a series of three patients with PAH. The participants had reduced anxiety and joint pain, as well as improved health promoting behaviours but the sample size was too small to perform statistical analysis. Additionally, (11) conducted a literature review and concluded that appropriately prescribed exercise is likely safe and beneficial for people with PAH, but that more research is needed.Taken together, the existing evidence suggests aerobic exercise and modified yoga have beneficial effects on fatigue, psychological and physical functioning in patients with PAH. But larger randomized controlled trials are required before such interventions can be routinely recommended.

VI. CONCLUSION

Pulmonary arterial hypertension is a complicated and multidimensional disease that should be identified and treated at an early stage. The progress in knowledge about its pathophysiology has resulted in the creation of specific therapies that have a serious positive impact on the patient. Nevertheless, PAH cannot be cured, which emphasizes the necessity to conduct further studies on the new treatment methods and possible medicines.

REFERENCES

[1] G. Simonneau *et al.*, "Updated clinical classification of pulmonary hypertension," *J. Am. Coll. Cardiol.*, 2013.

[2] N. Galiè *et al.*, "2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension," *Eur. Heart J.*, 2022.

[3] M. Humbert *et al.*, "Pathology and pathobiology of pulmonary hypertension," *Lancet Respir. Med.*, 2019.

[4] V. V. McLaughlin *et al.*, "ACCF/AHA expert consensus document on pulmonary hypertension," *Circulation*, 2009.

[5] M. M. Hoeper *et al.*, "Definitions and diagnosis of pulmonary hypertension," *J. Am. Coll. Cardiol.*, 2013.

[6] T. Thenappan *et al.*, "Epidemiology of pulmonary arterial hypertension," *Chest*, 2018.

[7] O. Sitbon *et al.*, "Long-term response to calcium channel blockers in pulmonary arterial hypertension," *Circulation*, 2005.

[8] L. J. Rubin, "Primary pulmonary hypertension," *N. Engl. J. Med.*, 1997.

[9] Weinstein *et al.*, "Exercise training improves fatigue and physical activity in patients with pulmonary arterial hypertension," *Respir. Med.*, vol. 107, no. 5, pp. 778–784, 2013.

[10] R. L. A. Awdish *et al.*, "Modified yoga for pulmonary arterial hypertension: A pilot case series," *Heart Lung*, vol. 44, no. 5, pp. 387–390, 2015.

[11] S. A. Desai and R. N. Channick, "Exercise in patients with pulmonary arterial hypertension," *J. Cardiopulm. Rehabil. Prev.*, vol. 28, no. 1, pp. 12–16, 2008.